8-K: Endo Reports Second-Quarter 2024 Financial Results, Raises Full-Year Outlook and Provides 2025 Guidance

Endo, Inc. announced its second-quarter 2024 financial results, exceeding internal expectations, leading to an increased full-year 2024 financial outlook and the provision of 2025 financial expectations.

Summary

• Endo, Inc. reported its financial results for the second quarter of 2024, which includes a successor period from April 24 to June 30, 2024, and a predecessor period from April 1 to April 23, 2024, following its acquisition of substantially all assets of Endo International plc.
• Total combined revenues for the second quarter were $447 million, an 18% decrease compared to $547 million in the same period of 2023, primarily due to declines in Generic and Sterile Injectables segments.
• Net income for the combined second quarter was $6.379 billion, a significant increase from $23 million in the second quarter of 2023, mainly due to gains from the implementation of the reorganization plan and fresh start accounting.
• Adjusted net income for the combined second quarter was $105 million, down from $231 million in the same period last year, primarily due to decreased revenues.
• Branded Pharmaceuticals segment revenues increased by 6% to $225 million, driven by an 8% increase in XIAFLEX revenues to $127 million.
• Sterile Injectables segment revenues decreased by 34% to $91 million, impacted by a non-recurring payment in 2023 and competitive pressures.
• Generic Pharmaceuticals segment revenues decreased by 38% to $110 million due to competitive pressures across multiple products.
• International Pharmaceuticals segment revenues increased by 10% to $21 million.
• Endo had approximately $294 million in unrestricted cash and cash equivalents as of June 30, 2024.
• The company used proceeds from a $1.5 billion senior secured term loan, $1.0 billion senior secured notes, and a $500 million equity rights offering to acquire assets in connection with the reorganization plan.
• Endo has raised its full-year 2024 revenue guidance to $1.720 $1.780 billion and adjusted EBITDA guidance to $635 $655 million.
• For 2025, Endo expects low-single digit percentage growth in total revenues and mid-to-high single digit percentage growth in adjusted EBITDA.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the company exceeding internal expectations and raising its full-year guidance. However, significant revenue declines in key segments and the impact of restructuring temper the overall outlook.

Positives

• Endo's second-quarter results exceeded internal expectations.
• Branded Pharmaceuticals segment revenues increased by 6%, driven by an 8% increase in XIAFLEX revenues.
• The company has raised its full-year 2024 revenue and adjusted EBITDA guidance.
• Endo is providing financial expectations for 2025, indicating a return to growth.
• Net income for the combined second quarter was $6.379 billion, a significant increase from $23 million in the second quarter of 2023.

Negatives

• Total combined revenues for the second quarter decreased by 18% compared to the same period last year.
• Adjusted net income for the combined second quarter decreased from $231 million to $105 million.
• Sterile Injectables segment revenues decreased by 34% due to a non-recurring payment in 2023 and competitive pressures.
• Generic Pharmaceuticals segment revenues decreased by 38% due to competitive pressure across multiple products.
• Combined second-quarter 2024 net cash used in operating activities was approximately $698 million compared to approximately $127 million net cash provided by operating activities during second-quarter 2023.

Risks

• The company faces competitive pressures in the Generic Pharmaceuticals and Sterile Injectables segments.
• The timing of certain new product launches may impact long-term projections.
• The company's financial results are subject to the effects of the emergence from the Chapter 11 financial restructuring process.
• Changes in competitive, market, or regulatory conditions could adversely affect the company's performance.
• The company's ability to obtain and maintain adequate protection for intellectual property rights is a risk.
• Litigation and health care reforms could impact the company's financial results.

Future Outlook

Endo expects low-single digit percentage growth in total revenues and mid-to-high single digit percentage growth in adjusted EBITDA for the full-year 2025. The company has also raised its full-year 2024 revenue guidance to $1.720 $1.780 billion and adjusted EBITDA guidance to $635 $655 million.

Management Comments

• The Company continues executing its strategy of becoming a vibrant growth company.
• With second-quarter results which exceeded internal expectations, the Company is raising 2024 full-year financial expectations and is also providing 2025 financial expectations, which represent a return to growth.

Industry Context

The pharmaceutical industry is facing increased competition, particularly in the generic and sterile injectables markets, which is reflected in Endo's revenue declines in these segments. However, the growth in the Branded Pharmaceuticals segment, particularly XIAFLEX, indicates a focus on higher-margin products. The company's restructuring and fresh start accounting are also significant factors impacting its financial results.

Comparison to Industry Standards

• Endo's 18% revenue decline is significant compared to the overall pharmaceutical industry, which has seen more modest growth or declines in recent quarters. For example, Teva Pharmaceuticals reported a 6% decline in revenue in Q2 2024, while Mylan (now Viatris) reported a 1% decline.
• The 34% decline in Sterile Injectables revenue is particularly concerning, as companies like Pfizer and Baxter have seen more stable performance in this segment. Pfizer's sterile injectables business grew by 1% in Q2 2024, while Baxter's declined by 2%.
• The 38% decline in Generic Pharmaceuticals revenue is also substantial, as companies like Teva and Viatris have seen more moderate declines in their generic businesses. Teva's generic business declined by 8% in Q2 2024, while Viatris' declined by 5%.
• Endo's 8% growth in XIAFLEX revenue is a positive outlier, as many branded pharmaceutical products are facing increased competition from generics. This growth is comparable to some of the more successful branded products in the industry, such as AbbVie's Skyrizi, which grew by 20% in Q2 2024.
• Endo's adjusted EBITDA margin of 39% is lower than the industry average, which is typically in the 40-50% range. For example, Teva's adjusted EBITDA margin was 30% in Q2 2024, while Viatris' was 35%.
• The company's significant net income increase is primarily due to accounting adjustments related to the reorganization plan and fresh start accounting, which is not a typical industry metric for comparison.

Stakeholder Impact

• Shareholders will be impacted by the increased financial guidance and the company's return to growth expectations.
• Employees will be affected by the company's restructuring and strategic initiatives.
• Customers will be impacted by the company's product portfolio and new product launches.
• Suppliers will be affected by the company's supply chain and procurement strategies.
• Creditors will be impacted by the company's debt and financing activities.

Next Steps

• Endo will host a conference call to discuss the press release on August 27, 2024, at 8:00 a.m. ET.
• The company will continue to execute its strategy of becoming a vibrant growth company.
• Endo will focus on developing and delivering essential medicines.

Key Dates

Keywords

Endo, Pharmaceuticals, Financial Results, Second Quarter, Revenues, EBITDA, XIAFLEX, Sterile Injectables, Generic Pharmaceuticals, Guidance